Our News
CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discoveryCambridge, UK, 26 April 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that...
The lung in crisis: fighting back against pathogens, infections and inflammation with predictive in vitro respiratory models that accelerate drug discovery
The human lung is in crisis Our lungs represent the only internal organ that is directly subject to the environment and therefore face a relentless battle against foreign matter. For centuries, they have been assaulted by enemies – both natural and synthetic....
Debunking the 9 Myths of Organ-on-a-Chip Technology
Organ-on-a-chip (OOC) technology offers you a transformative approach to better science. By bridging the gaps between traditional cell culture, animal models and the clinic, its complementary use offers the promise of deeper, human-relevant insights and more informed...
De-risking drug-induced liver injury through the predictive power of organ-on-a-chip
The liver is responsible for metabolizing most medications, and as such represents one of the primary tissues affected by adverse drug reactions. Drug-induced liver injury (DILI) is a potential complication of nearly all classes of medication. Unfortunately, it's not...
PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′
Next generation Organ-on-a-Chip technology listed second in Top 10 Innovations for 2021 System enables pre-clinical studies that simulate complex interaction and communication between organs, such as liver, gut, lung, and kidney, for accelerated drug discovery and...
CN Bio and iiCON announce COVID-19 research collaboration
Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models developed using Innovate UK grant 3D lung cell culture technology to support more efficient and accurate COVID-19 therapeutic...
CN Bio expands service offering to support oncology drug discovery
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system Represents first implementation of intellectual property licensed from Vanderbilt University to provide human-relevant...
Changing Times, Why Pharmacokinetics Matter in Drug Discovery
Drug discovery should be simple. Deliver the right molecule, antibody, new modality, or cell to the right target within the right organ at the right concentration. Once you have ensured there are no unwanted effects elsewhere in the body, you have developed a safe and...
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect on human health Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ...
Lonza and CN Bio Announce Distribution Agreement
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM...